



| Revenue | $100 - $500 million See Exact Annual Revenue |
|---|---|
| Employees | 500 - 1,000Exact Company Size |
| Primary Industry | 5417 Scientific Research & Development Services |
| Address | 3535 General Atomics Ct Suite 200 San Diego, CA 92121 |
| Fate Therapeutics | Revenue Est. ($ Million) | Growth Rate (%) | # Employees |
|---|---|---|---|
| 2025 | $100 - $500 million Details in Premium Report | ||
| 2024 | |||
| 2023 | |||
| 2021 | |||
| 2020 | |||
| 2019 | |||
|
1-Year Growth Rate: 3-Year Growth Rate (CAGR): | ![]() |
| Fate Therapeutics P&L | $ Millions |
|---|---|
| Revenue (Sales) | ![]() |
| Cost of Goods Sold | |
| Gross Profit | |
Operating Expenses | |
| Advertising | |
| Salaries and wages | |
| Other Operating Expenses | |
| Total Operating Expenses | |
| Operating Income | |
| EBITDA | |
| EBIT (Earnings Before Interest and Taxes) | |
| Net Profit | |
| Trademark | Date |
|---|---|
| NKAR pharmaceutical preparations for the treatment of cancer; therapeutic agents for the treatment of cancer; cells and cell-derived preparations for medical, clinical, and therapeutic use; cells and cell-derived preparations for clinical, medicinal, and therapeutic purposes; biological preparations for therapeutic purposes; biological preparations for a therapeutic material, namely, cell lines used for medical cell therapy; pharmaceutical preparations and substances for the treatment of immunological diseases and cancer | 04/02/2019 |
| TFINITY Cells for medical use; therapeutic cell preparation for the treatment of cancer, infectious diseases, and immune disorders; therapeutic agents for the modulation of cells for use as immunotherapies; pharmaceutical preparations for the treatment of cancer, infectious diseases, and immune disorders; kits comprised of cells and pharmaceutical preparations for the treatment of cancer, infectious diseases, and immune disorders for medical or clinical use; bio-engineered component for a therapeutic material, namely, cell lines for medical or clinical use used for immunotherapy | 08/18/2016 |
| TOLERACYTE stem cells for medical purposes; therapeutic cell preparation for the treatment of auto-immune diseases, and inflammatory and immune disorders; therapeutic agents for the modulation of cells for use as immunotherapies | 06/06/2016 |
| Company | Headquarters | Revenue ($ MM) |
|---|---|---|
| LEIDOS | Denver, CO | 100 |
| NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA | Albuquerque, NM | 30 |
| INC RESEARCH | Raleigh, NC | 27 |
| RESEARCH FOUNDATION FOR STATE UNIVERSITY OF NEW YORK | Albany, NY | 17 |
| FLUOR MARINE PROPULSION | West Mifflin, PA | 15 |
| SYNEOS HEALTH | Raleigh, NC | 13 |
| ILLUMINA | San Diego, CA | 12 |
| UT-BATTELLE | Oak Ridge, TN | 11 |
| PRA HOLDINGS | Raleigh, NC | 11 |
| Company | Headquarters | Revenue ($ MM) |
|---|---|---|
| ILLUMINA | San Diego, CA | 100 |
| NEUROCRINE BIOSCIENCES | San Diego, CA | 23 |
| SANTARUS | San Diego, CA | 16 |
| HALOZYME THERAPEUTICS | San Diego, CA | 15 |
| MIRATI THERAPEUTICS | San Diego, CA | 12 |
| FATE THERAPEUTICS | San Diego, CA | 11 |
| Company | Revenue ($ MM) |
|---|---|
![]() | |